United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at Cowen Health Care Conference Transcript

Mar 11, 2019 / 08:10PM GMT
Release Date Price: €97.98 (-0.10%)
Chris Shibutani;James C. Edgemond
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst;United Therapeutics Corporation - CFO &

Good afternoon. Why don't we get started. My name is Chris Shibutani. I'm a member of the Cowen Biotech Equity Research team. We're very excited to have United Therapeutics join us once again. I think when you think about the whole scope of the companies in the biotech space, the term franchise really aptly applies to them. This is a company that really was a pioneer that created so many dimensions of this space. The entire portfolio cascades through meeting all the needs of patients.

The story continues to play out with investors kind of doing a tug-of-war over what to believe and what to be skeptical of, but nonetheless, I think what you're seeing is stock performance has actually been very resilient, and there's many opportunities ahead with additional pipeline readout that will continue to tell the story. We welcome James Edgemond, the CFO, to update us on United Therapeutics. Thanks for joining us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot